The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...
GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...
The studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The ...
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to ...
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
GSK's revenue and EPS exceeded my expectations and those of analysts. Check out the reasons why I am upgrading GSK stock's ...
GSK (GSK) plc announced that the Food and Drug Administration has approved Penmenvy for use in individuals aged 10 through 25 years. The ...
Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by ...
Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage ...